{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:40:56Z","timestamp":1792741256910,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.08.049","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T04:40:54Z","timestamp":1631076054000},"page":"162-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)"],"prefix":"10.1016","volume":"40","author":[{"given":"Heather L.","family":"Platt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-3131","authenticated-orcid":false,"given":"Miwa","family":"Haranaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Narejos Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M.","family":"Tamms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-3825","authenticated-orcid":false,"given":"Yaru","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-7037","authenticated-orcid":false,"given":"Luwy K.","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6671-0115","authenticated-orcid":false,"given":"Ulrike K.","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2021.08.049_b0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2021.08.049_b0010","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2021.08.049_b0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijid.2015.05.003","article-title":"Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence","volume":"37","author":"Curcio","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.049_b0020","unstructured":"Hamborsky, J., A. Kroger, and W. S., Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 2015: Washington D.C. Public Health Foundation."},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013\u201318","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.049_b0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","article-title":"Efficacy and Effectiveness of a 23-Valent Polysaccharide Vaccine Against Invasive and Non-Invasive Pneumococcal Disease and Related Outcomes","volume":"20","author":"Niederman","year":"2021","journal-title":"A Review of Available Evidence. Expert Review of Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2049936113518041","article-title":"Management of community-acquired pneumonia in older adults","volume":"2","author":"Simonetti","year":"2014","journal-title":"Therapeutic advances in infectious disease"},{"issue":"18","key":"10.1016\/j.vaccine.2021.08.049_b0040","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.049_b0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(04)00931-4","article-title":"Pneumonia in the very old","volume":"4","author":"Janssens","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.049_b0050","doi-asserted-by":"crossref","unstructured":"Falkenhorst, G., et al., Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One, 2017. 12(1): p. e0169368.","DOI":"10.1371\/journal.pone.0169368"},{"key":"10.1016\/j.vaccine.2021.08.049_b0055","doi-asserted-by":"crossref","unstructured":"Maruyama, T., et al., Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. Bmj, 2010. 340: p. c1004.","DOI":"10.1136\/bmj.c1004"},{"key":"10.1016\/j.vaccine.2021.08.049_b0060","doi-asserted-by":"crossref","unstructured":"Moberley, S., et al., Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev, 2013(1): p. Cd000422.","DOI":"10.1002\/14651858.CD000422.pub3"},{"issue":"10","key":"10.1016\/j.vaccine.2021.08.049_b0065","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.vaccine.2009.01.013","article-title":"Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study","volume":"27","author":"Vila-Corcoles","year":"2009","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2021.08.049_b0070","first-page":"1453","volume":"325","author":"Shapiro","year":"1991","journal-title":"The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine."},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.049_b0075","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"12","key":"10.1016\/j.vaccine.2021.08.049_b0080","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.049_b0085","doi-asserted-by":"crossref","first-page":"404","DOI":"10.14336\/AD.2018.0512","article-title":"Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults","volume":"10","author":"Marra","year":"2019","journal-title":"Aging and disease"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","article-title":"Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects","volume":"32","author":"Davis","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy872","article-title":"Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis","volume":"69","author":"Vadlamudi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2021.08.049_b0100","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.06.018","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in adults 65years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010\u20132016","volume":"36","author":"Demczuk","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.049_b0105","doi-asserted-by":"crossref","unstructured":"Vissers, M., et al., Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS One, 2018. 13(3): p. e0194823.","DOI":"10.1371\/journal.pone.0194823"},{"key":"10.1016\/j.vaccine.2021.08.049_b0110","doi-asserted-by":"crossref","unstructured":"Naucler, P., et al., Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis, 2017. 65(11): p. 1780-1789.","DOI":"10.1093\/cid\/cix685"},{"issue":"6","key":"10.1016\/j.vaccine.2021.08.049_b0115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/cid\/cix446","volume":"65","author":"Schroeder","year":"2017","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"29","key":"10.1016\/j.vaccine.2021.08.049_b0120","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.vaccine.2017.05.049","article-title":"Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study","volume":"35","author":"LeBlanc","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.049_b0125","doi-asserted-by":"crossref","unstructured":"Slotved, H.C., et al., The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon, 2016. 2(11): p. e00198.","DOI":"10.1016\/j.heliyon.2016.e00198"},{"key":"10.1016\/j.vaccine.2021.08.049_b0130","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3389\/fmicb.2016.01616","article-title":"Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012\u20132014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes","volume":"7","author":"Hor\u00e1cio","year":"2016","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.049_b0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.049_b0140","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm","volume":"47","author":"Galanis","year":"2016","journal-title":"Sweden. Eur Respir J"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.049_b0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2010.10.032","article-title":"Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease","volume":"29","author":"Yildirim","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.049_b0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.049_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.049_b0160","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Human vaccines & immunotherapeutics"},{"key":"10.1016\/j.vaccine.2021.08.049_b0165","doi-asserted-by":"crossref","unstructured":"Platt, H.L., et al., A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J, 2020. 39(8): p. 763-770.","DOI":"10.1097\/INF.0000000000002765"},{"issue":"45","key":"10.1016\/j.vaccine.2021.08.049_b0170","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u226550 years of age","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.049_b0175","year":"2007","journal-title":"Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials; Available from:\u00a0 https:\/\/www.fda.gov\/media\/73679\/download [accessed 29 January 2021]"},{"issue":"19","key":"10.1016\/j.vaccine.2021.08.049_b0180","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"14","key":"10.1016\/j.vaccine.2021.08.049_b0185","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4155\/bio-2020-0024","article-title":"Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.vaccine.2021.08.049_b0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.08.049_b0195","unstructured":"Liang, K.-Y. and S.L. Zeger, Longitudinal Data Analysis of Continuous and Discrete Responses for Pre-Post Designs. Sankhy\u0101: The Indian Journal of Statistics, Series B (1960-2002), 2000. 62(1): p. 134-148."},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.049_b0200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The Use of Confidence of Fiducial Limits Illustrated in the Case of the Binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2021.08.049_b0205","doi-asserted-by":"crossref","unstructured":"Hurley, D., et al., Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis, 2020.","DOI":"10.1093\/cid\/ciaa1045"},{"issue":"35","key":"10.1016\/j.vaccine.2021.08.049_b0210","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0215","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4161\/hv.34420","article-title":"Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly","volume":"11","author":"Durando","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2021.08.049_b0220","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults >\/=65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.08.049_b0225","article-title":"The Proportion of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in UK Adults Potentially Covered by the 13-Valent and Next-Generation Higher-Valency Pneumococcal Conjugate Vaccines Under Development","author":"Vyse","year":"2020","journal-title":"ISPPD-12."},{"issue":"21","key":"10.1016\/j.vaccine.2021.08.049_b0230","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","article-title":"Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults","volume":"32","author":"Grabenstein","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.08.049_b0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.08.049_b0240","doi-asserted-by":"crossref","unstructured":"Weinberger, B., Vaccines for the elderly: current use and future challenges. Immunity & ageing : I & A, 2018. 15: p. 3-3.","DOI":"10.1186\/s12979-017-0107-2"},{"issue":"35","key":"10.1016\/j.vaccine.2021.08.049_b0245","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.08.049_b0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: The challenge of immune changes with aging","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21010975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:38Z","timestamp":1759403258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21010975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21010975"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}